Regu-Mate® suppresses estrus in 95 percent of mares after three days of treatment.¹ When treatment is discontinued, mares return to estrus within four to five days.

When everything is at stake, trust Regu-Mate® to:
- Help alleviate behavior associated with estrus
- Control estrous cycle in transitional mares for early-season breeding
- Synchronize estrous cycles for embryo transfer
- Suppress estrus in postpartum mares to help increase fertility
- Efficiently manage the estrous cycle to:
  - Reduce semen collections and handling
  - Decrease shipping costs
  - Reduce number of breedings per mare

Regu-Mate® — TRIED AND TESTED
- More than 200 clinical trials conducted to determine safety and efficacy
- More than 30 years of practical use in the field
- More than 50 million doses sold²

Trusted by Veterinarians for Good Reason
- Proven palatability, bioavailability and efficacy in EVERY dose
- Delivers safe, predictable control over a mare’s reproductive cycle
- 15-day treatment regimen reliably keeps mares from entering estrus¹
- Strategic use helps accommodate mare’s performance schedule
- Easy to administer

“I don’t want to be in doubt of whether an estrus suppression product is going to work or not and that is why I have stayed with Regu-Mate for 30-plus years. I have always found it to be a very dependable and trustworthy product for a variety of situations.”

- Glenn Blodgett, D.V.M., Guthrie, Texas

“I’ve been using Regu-Mate since I graduated from veterinary school. No matter the discipline or the use... I am concerned with ease of use, efficacy of the formation and consistency of the product. All of those boxes are checked with Regu-Mate.”

- David B. Scofield, D.V.M., M.S., Dipl. ACT, Chesapeake City, Md.

“My clients expect top-of-the-line care from me and I, in turn, expect that from products that I recommend. I have no question in my mind that Merck Animal Health has quality control practices in place to ensure that I am handing my clients a product with consistent quantity and quality of the active ingredient (altrenogest), which is imperative to protect my clients’ investment in their horses.”

- Corey D. Miller, D.V.M., M.S., Dipl. ACT, Ocala, Fla.

¹ Regu-Mate (altrenogest) product label.
² Data on file, Merck Animal Health.

Contact your Merck Animal Health sales representative or call 1-800-521-5767 for more information.
Merck-Animal-Health-Equine.com
Regu-Mate® is contraindicated for use in mares having a previous or current history of uterine inflammation. When treatment is discontinued, mares exhibiting regular estrus cycles return to estrus within 4 to 5 days following treatment and continue to cycle normally. Pregnant women or women who suspect they are pregnant should not handle Regu-Mate®.

**Solution 0.22% (2.2 mg/mL)**

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** Regu-Mate® (altrenogest) Solution 0.22% contains the active synthetic progestin, altrenogest. The chemical name is 1,4 dihydro-4-oxo-1,2,3,4- tetrahydro-1-aza-2,4-cyclohexadiene-3-carboxylic acid. The CAS Registry Number is 850-52-2. The chemical structure is:

Each ml of Regu-Mate® (altrenogest) Solution 0.22% contains 2.2 mg of altrenogest in an oil solution.

**INDICATIONS:** Regu-Mate® (altrenogest) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus provides a valuable occurrence of estrus for following drug withdrawal. This facilitates the attainment of regular cyclical cycles during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be helpful to facilitate scheduled breeding during the physiological breeding season.

**CONTRAINDICATIONS:** Regu-Mate® (altrenogest) Solution 0.22% is contraindicated for use in mares having a previous or current history of uterine inflammation (i.e., acute, subacute, or chronic endometritis). Natural or synthetic gestagen therapy may exacerbate existing low-grade or “smoldering” uterine inflammation into a fulminating uterine infection in some instances.

**PRECAUTIONS:** Various synthetic progestins, including altrenogest, when administered to rats during the embryonic stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically masculinization of the female genitalia.

**DOSAGE AND ADMINISTRATION:** While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect hepar lock syringe (without needle). Draw out appropriate volume of Regu-Mate® solution. (Note: Do not remove syringe while bottle is inverted as spillage may result.) Detach syringe and administer solution orally at the rate of 1 mL per 110 pounds body weight (0.044 mg/kg) once daily for 15 consecutive days. Administer solution directly to the base of the mare’s tongue or on the mare’s usual grain ration. Replace cover on bottle dispensing tip to prevent leakage. Excessive use of a syringe may cause the syringe to stick; therefore, replace syringe as necessary.

**WHICH MARES WILL RESPOND TO REGU-MATE® (ALTRENOGEST) SOLUTION 0.22%:** Extensive clinical trials have demonstrated that estrus will be suppressed in approximately 95% of the mares within three days. However, the post-treatment response depends on the level of ovarian activity when treatment was initiated. Estrus in mares exhibiting regular estrus cycles during the breeding season will be suppressed during treatment; these mares return to estrus four to five days following treatment and continue to cycle normally. Mares in winter anestrus with small follicles continued in anestrus and failed to exhibit normal estrus following withdrawal. Response in mares in the transition phase between winter anestrus and the summer breeding season depended on the degree of follicular activity. Mares with inactive ovaries and small follicles failed to respond with normal cyclical post-treatment, whereas a higher proportion of mares with ovulation follicles 20 mm or greater in diameter exhibited normal estrus cycles post-treatment. Regu-Mate® (altrenogest) Solution 0.22% was very effective for suppressing the prolonged estrus behavior frequently observed in mares during the transition period (February, March, and April). In addition, a high proportion of these mares responded with regular estrus cycles post-treatment.

**SPECIFIC USES FOR REGU-MATE® (ALTRENOGEST) SOLUTION 0.22%:**

1. Facilitate management of regular estrus cycles during the transition period from winter anestrus to the physiological breeding season. To facilitate attainment of regular cycles during the transition phase, mares should be examined to determine the degree of ovarian activity. Estrus in mares with inactive ovaries (no follicles greater than 20 mm in diameter) will be suppressed but these mares may not begin regular cycles following treatment. However, mares with active ovaries (follicles greater than 20 mm in diameter) frequently respond with regular post-treatment estrus cycles.

2. Facilitate management of the mare exhibiting prolonged estrus during the transition period. Estrus will be suppressed in mares exhibiting prolonged behavioral estrus either early or late during the transition period. Again, the posttreatment response depends on the level of ovarian activity. The mares with greater ovarian activity initiate regular cycles and conceive sooner than the inactive mares. Regu-Mate® (altrenogest) Solution 0.22% may be administered early in the transition period to suppress mares in irregular estrus to aid in the management of these mares or to mares later in the transition period with active ovaries to prepare and schedule the mare for breeding.

3. Permit scheduled breeding of mares during the physiological breeding season. To permit scheduled breeding, mares which are regularly cycling and which have active ovarian function should be given Regu-Mate® (altrenogest) Solution 0.22% daily for 35 consecutive days beginning 20 days before the date of the planned estrus. Ovulation will occur up to 7 days following the onset of estrus for mares prevented from cycling.

Breedingshould befollowedon proceduresformaresin estrus. Mares may be regulated and scheduled either individually or in groups.

**ADDITONAL INFORMATION:** A 3-year well controlled reproductive safety study was conducted in 27 pregnant mares, and compared with 24 untreated control mares. Treated mares received 2 ml Regu-Mate® (altrenogest) Solution 0.22% /110 lb body weight (2x dosage recommended for estrus suppression) from day 20 to day 325 of gestation. This study provided the following data:

1. In mares (all ages) of treated mares, citteral size was increased.
2. Mares that were treated for estrus suppression from day 20 to day 28 showed follicle suppression from their untreated mare counterparts.
3. There were no significant differences in reproductive performance between treated and untreated animals (mares and their respective offspring) measured in the following parameters:
   - interval from Feb. 1 to first ovulation, in mares only.
   - mean interval between first to second cycle and second to third cycle, mares only.
   - follicle size, mares only.
   - 50 days gestation, pregnancy rate in treated mares was 81.8% /11 untreated mares was 50% (4/4).
   - after 3 cycles, 1/12 treated mares were pregnant (91.7%) and 4/4 untreated mares were pregnant (100%).
   - all offspring from treated and control mares showed no differences in seminal volume, spermatozoal concentration, spermatozoal motility, and total sperm per ejaculate.
   - offspring from treated and control mares showed no difference in sexual behavior.
   - testicular characteristics (testis weight, spermatozoal weight, parenchymal weight, epididymal weight and height, testicular weight, length) were the same between stallion offspring of treated and control mares.

**REFERENCES:**


**WARNING:** Do not use in horses intended for food.

**HUMAN WARNINGS:** Skin contact must be avoided as Regu-Mate® (altrenogest) Solution 0.22% is readily absorbed through unbroken skin. Protective gloves must be worn by all persons handling this product. Pregnant women or women who suspect they are pregnant should not handle Regu-Mate® (altrenogest) Solution 0.22%. Women of child-bearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

**INFORMATION FOR HANDLERS:**

**WARNING:** Regu-Mate® (altrenogest) Solution 0.22% is readily absorbed by the skin. Skin contact must be avoided; protective gloves must be worn when handling this product.

**Effects of Overexposure:** There has been no human use of this specific product. The information contained in this section is extrapolated from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the pharmacological activity of altrenogest. Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complications if swallowed. In addition, the list of people who should not handle this product (see below) is based upon the known effects of progestins used in humans on a chronic basis.

**PEOPLE WHO SHOULD NOT HANDLE THIS PRODUCT.**

1. Women who are or suspect they are pregnant.
2. Anyone with thromboplastic disorders or with a history of these events.
3. Anyone with cerebral-vascular or coronary artery disease.
4. Women with undiagnosed vaginal bleeding.
5. Women with cerebral-vascular or coronary artery disease.
6. Women with undiagnosed vaginal bleeding.
7. Women with benign or malignant tumors which developed during the use of oral contraceptives or other estrogen-containing products.
8. Anyone with liver dysfunction or disease.

**ACCIDENTAL EXPOSURE:** Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact rubber or impermeable gloves; however, if there is leakage (i.e., pinhole, spillage, etc.), the contaminated area covered by such occlusive materials may have increased absorption. The following measures are recommended in case of accidental exposure.

**Skin Exposure:** Wash immediately with soap and water. 

**Eye Exposure:** Immediately flush with plenty of water for 15 minutes. Get medical attention.

**Food Exclusion:** Do not induce vomiting. Regu-Mate® (altrenogest) Solution 0.22% contains an oil. Call a physician.

**Vomiting:** Should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to the physician.

**CAUTION:** For oral use in horses only. Keep this and all medication out of the reach of children.

**Store at or below 70 °F (77 °F).**

**NADA** 131.310. Approved by FDA.

**HOW SUPPLIED:** Regu-Mate® (altrenogest) Solution 0.22% (2.2 mg/mL). Each ml contains 2.2 mg altrenogest in an oil solution. Available in 1000 mL plastic bottles.

* US Patents 3,453,267; 3,478,067; 3,484,462

Manufactured for Internet Inc (d/b/a Merc Merck Animal Health), Summit, NJ 07901

Made in France